Fig. 6

Monitoring of lung cancer progression and response to therapy through longitudinal plasma ctDNA sequencing. a Compared with ctDNA mutations in five patients at two different time points, top shows the patients’ number and relative time point. Four patients demonstrated EGFR mutations. Mutation burden of patients 2 and 3 decreased after treatment. b Serial imaging at the time of plasma ctDNA testing indicated partial response for patient 3, minor response for patient 2, and progressive disease for patients 1, 4, and 5